急性缺血性卒中血管内介入治疗的患者选择

Patients selection for endovascular therapy in acute ischemia stroke

在发病4．5h内使用重组组织型纤溶酶原激活剂进行静脉溶栓是目前唯一被证实有效的急性缺血性卒中治疗措施，但对大血管病变的血管再通率较低。在这种情况下，急性缺血性卒中的血管内介入治疗得以飞速发展，因为后者能够明显提高血管再通率。然而，任何治疗措施都是双刃剑，没有最好的治疗措施，只有最合适的治疗措施。本文将回顾相关文献，对如何选择适合行血管内介入治疗的急性缺血性卒中患者进行综述。

Currently, intravenous tissue plasminogen activator within 4. 5 hours of stroke onset is the only proven treatment for acute ischcmic stroke. However, recanalization rate within 24 hours after the administration of intravenous tissue plasminogen activator is low, especially when the occlusion site involves a large intracranial artery. The low recanalization rate has prompted the development of endovascuiar therapy. Nevertheless, all treatment is binary, there is no best but most suitable treatment. In this article we review available researches on endovascular therapy and patients selection for endovascular therapy.